Sotagliflozin
Back to searchMolecule Structure
Scientific Name
Sotagliflozin
Description of the Drug
Sotagliflozin is an orally administered dual SGLT1/2 inhibitor used alongside insulin to improve glycemic control in patients with type 1 diabetes mellitus.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB12713
http://www.drugbank.ca/drugs/DB12713
Brand Name(s)
Not Available
Company Owner(s)
Not Available
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| Sodium/glucose cotransporter 1 | SINGLE PROTEIN | INHIBITOR | CHEMBL4979 |
| Sodium/glucose cotransporter 2 | SINGLE PROTEIN | INHIBITOR | CHEMBL3884 |
Clinical Trial(s)
Unichem Links
| SureChEMBL | SCHEMBL1038287 |
| DrugBank | DB12713 |
| PubChem: Thomson Pharma | 49853536 |
| PubChem | 24831714 |
| BindingDB | 50235017 |
| EPA CompTox Dashboard | DTXSID20144314 |
| DrugCentral | 5339 |
| ChemicalBook | CB52516025 |
| Guide to Pharmacology | 8312 |
| ZINC | ZINC000095641922 |
